MONO6

    Chapter 10-Review of State of the Art: Growth Factor-Based Systems for Use as Bone Graft Substitutes

    Published: Jan 2003

      Format Pages Price  
    PDF (1.9M) 20 $25   ADD TO CART
    Complete Source PDF (32M) 20 $154   ADD TO CART


    Abstract

    IN 1965 MARSHALL R. URIST [1] FIRST demonstrated that osteoinductive substances led to the formation of bone at extraskeletal sites, by observing that a new ossicle had formed after the implantation of demineralized bone matrix in a muscle pouch of a rat. Less than two decades later, Sampath and Reddi [2] in an in vivo bioassay separated insoluble demineralized bone matrix from the soluble morphogenetic protein responsible for this effect, which was named bone morphogenetic protein. Seven years later, Wozney et al. [3] identified the genetic sequence of bone morphogenetic protein, leading to the discovery of its different isoforms and later, in 1990 osteogenetic protein (OP-1) was cloned by Ozkaynak et al. [4].


    Author Information:

    Attawia, M

    Rosier, R

    Cheung, EV
    School of Medicine, Drexel University, Philadelphia, PA

    Katti, DS
    School of Medicine, University of Virginia, Charlottesville, VA

    Rosier, RN
    University of Rochester, Rochester, NY

    Laurencin, CT
    School of Medicine, Drexel University, Philadelphia, PA

    School of Medicine, University of Virginia, Charlottesville, VA


    Paper ID: MONO10067M

    Committee/Subcommittee: F04.21

    DOI: 10.1520/MONO10067M


    CrossRef ASTM International is a member of CrossRef.

    ISBN10: 0-8031-3356-1
    ISBN13: 978-0-8031-3356-3